ZURICH - Roche won U.S. approval on Friday of its immunotherapy Tecentriq to treat a significant number of patients with triple-negative breast cancer, a development hailed by doctors as a promising advance in fighting the aggressive disease.
Roche’s Tecentriq has fallen well behind immunotherapies Keytruda from Merck and Opdivo from Bristol-Myers Squibb in treatment areas such as lung cancer. It hopes beating the two rival therapies in less common diseases like triple-negative breast cancer will help its medicine’s revenue accelerate. More than 250,000 cases of invasive breast cancer are diagnosed annually in the United States, some 15 percent of which are triple-negative.
marekani kumbe wana TFDA
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Roche's Tecentriq wins U.S. approval for aggressive breast cancerRoche won U.S. approval on Friday of its immunotherapy Tecentriq to treat a sign... Yet just 3 months later, a huge splash of cold water with the release of new data at ASCO showing no statistically significant overall survival benefit. In March I explained US_FDA shouldn't use surrogate endpoints like PFS for approvals:
Source: Reuters - 🏆 2. / 97 Read more »
Roche's Tecentriq wins U.S. approval for aggressive breast cancerRoche won U.S. approval on Friday of its immunotherapy Tecentriq to treat a sign... Yet just 3 months later, a huge splash of cold water with the release of new data at ASCO showing no statistically significant overall survival benefit. In March I explained US_FDA shouldn't use surrogate endpoints like PFS for approvals:
Source: Reuters - 🏆 2. / 97 Read more »
US Aid Cuts Are Making It Harder For Palestinian Women To Treat Their Breast CancerMore than 1,000 women who had mammograms done through a US-funded program and were flagged for follow-ups have had to seek other treatment options. Sad
Source: BuzzFeed - 🏆 730. / 51 Read more »
FDA approves first immunotherapy regimen for breast cancerThe US Food and Drug Administration granted its first approval to an immunotherapy regimen for breast cancer, the agency announced Friday. The drug, Genentech's Tecentriq, was approved for use in combination with Abraxane chemotherapy for patients who have a type of advanced triple negative breast cancer. Ok but can we get a better less painful breast screening? The smash'em up titty twisting is getting fucking old. How about we put men's nutsac in for cancer screening? I bet then they'd find a less painful way to screen? Hard to trust the FDA... They assisted in creating an opioid epidemic... Maybe they should pick cancers with a higher mortality rate like GBM, pancreatic... GBM has a 5% survival rate at 5 years...
Source: CNN - 🏆 4. / 95 Read more »